ALSO IN THIS MONTH'S ISSUE

• Democratic And Republican Health Priorities In The Next Administration

  With the conventions and a contentious summer behind them, both political parties are laying out their agendas for the next four years. What are the Democratic and Republican health priorities?

• Changing The Status Quo Regarding Diversity In Clinical Trials

  Encouraging patients of all races and genders to enroll in clinical trials has been a challenge for years. So, what can be done?

• Why COGs Will Demand More Attention From Biosimilar Makers

  Without continued innovation in the manufacturing and analytical components of biosimilar development, the biosimilar value proposition becomes less feasible for pharma manufacturers.

• Companies To Watch: Osivax

  Osivax is developing universal vaccines for influenza, coronaviruses, and other infectious diseases such as malaria and human papillomavirus (HPV). Preclinical studies also have started on a coronavirus vaccine, which would include Covid-19.